RxDoctor Payments Data

Adalbert Pilip, MD

Internal Medicine · Smithtown, NYNPI 1548424039

Payments from drug & device makers

$8,672in general payments, 2019–2025

Across 430 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$925
  • Novartis$778
  • Abbott$627
  • Pfizer$440
  • Merck$423
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,661100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,672 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$691,136
Medicare patients
615
Services billed
5,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide158$156,899
EliquisApixaban57$71,572
MounjaroTirzepatide48$52,590
XareltoRivaroxaban31$40,668
EntrestoSacubitril/Valsartan17$30,008
Repatha SureclickEvolocumab52$28,229
JanuviaSitagliptin Phosphate19$27,607
WegovySemaglutide19$24,179
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$22,693
JardianceEmpagliflozin12$21,063
FarxigaDapagliflozin Propanediol12$16,882
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,447
Breo ElliptaFluticasone/Vilanterol15$5,878
Atorvastatin Calcium556$4,756
Azelastine Hcl163$3,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$353$181,077177 claims
PfizerEliquis$440$71,57257 claims
Lilly USA, LLCMounjaro$241$52,59048 claims
Johnson & JohnsonXarelto$256$40,66831 claims
NovartisEntresto$778$30,00817 claims
GSKTrelegy Ellipta, Breo Ellipta$925$28,57134 claims
MerckJanuvia$423$27,60719 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,852$24,32924 claims
Boehringer IngelheimJardiance$308$21,06312 claims
AbbVieSynthroid$28$1,24416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Smithtown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →